ADVFN - Advanced Financial Network.
HOME» NASDAQ » A » ACOR Stock Price » ACOR Stock News

Acorda Therapeutics Share News

 Acorda Therapeutics (mm) Stock Price
ACOR Stock Price
 Acorda Therapeutics (mm) Stock Chart
ACOR Stock Chart
 Acorda Therapeutics (mm) Stock News
ACOR Stock News
 Acorda Therapeutics (mm) Company Information
ACOR Company Information
 Acorda Therapeutics (mm) Stock Trades
ACOR Stock Trades

FDA OKs Ampyra To Improve Walking In Adults With Multiple Sclerosis

By Jennifer Corbett Dooren Of DOW JONES NEWSWIRES WASHINGTON -(Dow Jones)- The U.S. Food and Drug Administration Friday approved a new drug from Acorda Therapeutics Inc. (ACOR) to improve walking in patients with multiple sclerosis. The FDA said the drug, Ampyra, is the first drug approved to improve walking in MS patients. The agency said clinical trials showed patients treated with Ampyra had faster walking speeds than those treated with a placebo or fake pill. Multiple sclerosis is a progressive disease that involves damage to nerves controlling muscles and vision; it affects about 400,000 Americans. The condition causes the body's immune system to eat away at the protective covering of the nerves, or myelin, which disrupts the electrical signals between the brain and the rest of the body. Ampyra is designed to help the body's electric signals pass through by blocking potassium ions that leak from the damaged nerves. The FDA said the product will be manufactured under licenses from Elan Corp. PLC (ELN) of Dublin, Ireland, and distributed by Acorda, Hawthorne, N.Y. Acord shares recently rose 9% to $28. -By Jennifer Corbett Dooren, Dow Jones Newswires; 202-862-9294;

Stock News for Acorda Therapeutics (ACOR)
05/27/201507:01:46Current Report Filing (8-k)
05/26/201507:00:00Acorda Therapeutics to Present at the Jefferies Global Healthcare...
05/15/201517:39:40Statement of Changes in Beneficial Ownership (4)
05/08/201517:25:03Quarterly Report (10-q)
05/05/201507:00:00Acorda Therapeutics to Present at the Bank of America Merrill...
05/01/201507:00:00Acorda Therapeutics to Present at the Deutsche Bank 40th Annual...
05/01/201503:37:14Canaccord Genuity Reaffirms Hold Rating for Acorda Therapeutics...
05/01/201503:14:17Acorda Therapeutics Receives Neutral Rating from JPMorgan Chase...
04/30/201506:51:30Current Report Filing (8-k)
04/30/201506:00:00Acorda Reports First Quarter 2015 Financial Results
04/23/201507:00:00Acorda Therapeutics to Host Conference Call to Discuss First...
04/22/201507:56:12Current Report Filing (8-k)
04/22/201507:30:00Acorda Presents Data on First Clinical Study of Remyelinating...
04/22/201507:01:00Acorda Therapeutics Named One of the Best Places to Work For...
04/22/201504:49:35Acorda Therapeutics Research Coverage Started at Piper Jaffray...
04/19/201514:07:03This New Hedge Fund Strategy Just Might Be Crazy Enough To Work
04/19/201513:01:02Will This Hedge Fund Manager Bring Down Your Biotech Stocks?
04/08/201512:55:14Confidential Treatment Order (ct Order)
04/07/201519:51:27Kyle Bass's New Tack: Dispute the Patent, Short the Stock
04/07/201516:49:59Hedge-Fund Manager Challenges Jazz Pharmaceuticals Patent

Acorda Therapeutics and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations